Good health is a right that should not be restricted by gender, race, wealth, age or borders.

WE BACK CEO's WHO SHARE OUR VISION AND COMMITMENT.

Cross Border Impact Ventures aims to be the preferred investor for transformative health technology companies with the potential of meeting the needs of women, children and adolescents across global markets. We have partnered with Grand Challenges Canada to develop a world class platform that breaks the paradigm of who benefits from leading technologies. 


We strive to earn venture capital returns for our investors and to empower our portfolio companies to reach beyond their primary markets in the United States and Europe to reach more vulnerable populations in developing economies. We also invest in select developing market companies with reverse technology transfer potential. We work collaboratively with the CEOs of our portfolio companies and our networks to enable commercial success, promote gender equality and deliver measurable impact with creative approaches tailored to local contexts.

 In partnership with:

Grand Challenges Canada Logo.png

Contact Us

Email: info@crossborder.ventures

Phone: +1 (416) 583-5821

661 University Avenue, MaRs Centre, West Tower, Suite 1720, Toronto, ON M5G 1M1

Executive Team

ANNIE THÉRIAULT
PHD, CFA, ICD.D
Managing Partner

linkedin-icon.png

Annie is the Chief Investment Officer of Grand Challenges Canada and the Managing Director of the Every Woman Every Child Innovation Marketplace. She is an experienced venture capitalist, lender, and operator who has managed over $600M in assets over her career. Her expertise includes public and private markets capital formation and complex financial engineering.

DONNA PARR
MBA, ICD.D
Managing Partner

linkedin-icon.png

Donna has over 25 years of experience managing venture capital, growth equity and private debt investment portfolios of up to $1 billion, including managing two biotech related funds, being a member of 13 biotech company boards (of 35 board directorships). Her track record includes numerous exits and entrepreneurial expertise as part of a medtech start-up.

ia-50.png